Frailty in Older Patients with Transthyretin Cardiac Amyloidosis

Stéphanie Cazalbou1,2, Louise Naccache3, Sandrine Sourdet3

  • 1Department of Cardiology, University Hospital of Toulouse, 31400 Toulouse, France.

PubMed

Insights

Most older patients with transthyretin cardiac amyloidosis (ATTR-CA) are frail. Frail patients exhibit more severe symptoms, increased cardiac involvement, and poorer prognosis, necessitating tailored management strategies.

Area of Science:

  • Cardiology
  • Geriatrics
  • Internal Medicine

Background:

  • Transthyretin cardiac amyloidosis (ATTR-CA) prevalence rises with age.
  • The relationship between frailty and heart failure is increasingly acknowledged.
  • Assessing frailty in older ATTR-CA patients is crucial for management.

Purpose of the Study:

  • To compare clinical, biological, and echocardiographic features of elderly ATTR-CA patients using the G8 frailty tool.
  • To identify differences in disease severity and cardiac involvement based on frailty status.

Main Methods:

  • Retrospective study of 52 patients over 75 with confirmed ATTR-CA (Jan 2020 - Apr 2021).
  • Evaluated patients via blood tests, transthoracic echocardiography (TTE), and functional assessments (6MWD or CPET).
  • Calculated G8 frailty scores to categorize patients.

Main Results:

  • 75% of patients were identified as frail by the G8 score.
  • Frail patients had more severe NYHA stages (2.2 vs. 1.7, p=0.004) and higher Gilmore stages (62% stage 2/3, p=0.05).
  • Frail patients showed reduced global left ventricular strain (-11.7% vs. -14.9%, p=0.014) and thicker interventricular septum (18±2mm vs. 17±2mm, p=0.033).

Conclusions:

  • The G8 score identifies a high prevalence of frailty in older ATTR-CA patients.
  • Frail patients present with greater symptomatology, cardiac involvement, and worse prognosis.
  • Personalized cardiac management strategies are essential for frail ATTR-CA individuals.

Related Concept Videos

Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining,...
9.6K
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
436